|
|
|
|
Conversion of external ventricular drains to ventriculoperitoneal shunts after aneurysmal subarachnoid hemorrh
Data obtained in 80 consecutive adult patients who underwent conversion of an EVD to a VP shunt for post-SAH hydrocephalus between August 2002 and March 2007 were retrospectively reviewed.The study was approved by the local institutional...
|
|
|
ViroPharma To Present At The 20th Annual Piper
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (NASDAQ:VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare...
|
|
|
Combined efficacy of clarithromycin plus cefazolin or vancomycin against Staphylococcus aureus biofilms formed
Fujimura S et al.- Biofilm formation and eradication of S. aureus were monitored by scanning electron microscopy and using double-staining dyes, respectively. Although S. aureus biofilms were not eradicated by CLA, CFZ or VCM alone,...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare Conference at 1:30 P.M...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare Conference at 1:30 P.M...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
/PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare Conference at 1:30 P.M.ET on Wednesday,...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM - News) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare Conference at 1:30 P.M...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare Conference at 1...
|
|
|
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
EXTON, Pa., Nov.25 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 20th Annual Piper Jaffray Healthcare Conference at 1:30 P.M...
|
|
|
US FDA Committee rejects approval of Arpida's iclaprim
Arpida announced that the Anti-infective Drugs Advisory Committee of the US Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous iclaprim, an antibiotic currently in development for the treatment of...
|
|
|
Incidence and Characteristics of Vancomycin Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aur
All 982 methicillin-resistant Staphylococcus aureus strains collected from August 2006 to December 2007 were tested for vancomycin susceptibility by using 3-g/ml vancomycin brain heart infusion screening plates, a vancomycin...
|
|
|
Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model
Free drug serum concentrations of minocycline associated with the doses given to humans (100 mg every 12 hours for 24 hours) were simulated in an in vitro hollow-fiber pharmacokinetic model.Four strains of methicillin (meticillin)...
|
|
|
FDA Panel Backs Approval of Theravance Antibiotic
COLLEGE PARK, Md.- A panel of federal advisers Wednesday supported approval of Theravance Inc.'s injectable antibiotic telavancin, despite the potential for the drug to cause birth defects and kidney problems. The South San Francisco...
|
|
|
Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogen
In order to better understand the mechanism of daptomycin resistance, we generated a daptomycin-nonsusceptible derivative strain, strain 10*3d1 (MIC = 3.0 g/ml), by in vitro exposure of methicillin-resistant Staphylococcus aureus strain...
|
|
|
In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strai
TR-701 is the orally active prodrug of TR-700, a novel oxazolidinone that demonstrates four- to eightfold-greater activity than linezolid (LZD) against Staphylococcus and Enterococcus spp.In this study evaluating the in vitro sensitivity...
|
|
|
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
REINACH, Switzerland, November 20 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) announced today that the Anti-infective Drugs Advisory Committee of the U.S.Food and Drug Administration (FDA) has voted 17 to 2 against the approval of...
|
|
|
C. difficile infections more common, difficult to treat, but preventable
Key point: Clostridium difficile (C.difficile), the opportunistic pathogen that causes antibiotic-associated diarrhea, is more prevalent, virulent, and likely to cause death compared with 10 years ago. Finer points: CP Kelly and JT...
|
|
|
FDA: contrasting fortunes for novel antibiotics
FDA panel issues positive opinion on telavancin but votes against oritavancin.An FDA advisory committee has this week expressed its views on three novel antibiotics, Theravance's telavancin, Targanta's oritavancin and Arpida's iclaprim.
|
|
|
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
/PRNewswire-FirstCall/ -- Arpida announced today that the Anti-infective Drugs Advisory Committee of the U.S.Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous iclaprim, an antibiotic currently in...
|
|
|
FDA backs Theravance antibiotic, rejects Targanta's
'I voted yes because I think vancomycin is sort of a dying drug,' said W.Kemper Alston, an associate professor of medicine at the University of Vermont in Burlington. The FDA has noted its concerns that patients taking telavancin...
|
|
|
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
REINACH, Switzerland, November 20 /PRNewswire-FirstCall/ -- Arpida announced today that the Anti-infective Drugs Advisory Committee of the U.S.Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous...
|
|
|
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
REINACH, Switzerland, November 20 /PRNewswire-FirstCall/ -- Arpida announced today that the Anti-infective Drugs Advisory Committee of the U.S.Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous...
|
|
|
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
REINACH, Switzerland, November 20 /PRNewswire-FirstCall/ -- Arpida announced today that the Anti-infective Drugs Advisory Committee of the U.S.Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous...
|
